GE Healthcare invests in CardioDx, which makes genetic tests used to diagnose heart disease

GE invests in $5M in heart disease test maker

NEW YORK — General Electric Co.’s health care unit on Thursday announced a partnership with CardioDx, which develops genetic tests that are used in diagnosing heart disease.

GE Healthcare, which makes diagnostic and medical imaging products, said it invested $5 million in CardioDx through an equity fund that investa in healthcare technology companies.

CardioDx makes genetic tests that can be used in treatment of people with conditions including heart failure and coronary artery disease.

The company’s main product is Corus CAD, a genetic test that measures the likelihood a patient has obstructive coronary artery disease. That condition can cause heart attack or death. Corus CAD uses a blood test, and GE Healthcare said that it less invasive than some of the other methods used to diagnose coronary artery disease.

Shares of GE, which is based in Fairfield, Conn., fell 21 cents to $18.23 in morning trading Thursday.